Valuation: ImmuPharma plc

Market Cap 22.55M 30.52M 26.36M 24.79M 42.42M 2.92B 43.08M 291M 114M 1.46B 114M 112M 4.87B P/E 2024
-2.01x
P/E 2025 -16.8x
Enterprise Value 21.2M 28.69M 24.78M 23.31M 39.87M 2.74B 40.5M 274M 107M 1.38B 108M 105M 4.58B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
95.03%
Yield 2024 *
-
Yield 2025 -
1 day-2.30%
1 week-2.95%
Current month+0.98%
1 month-19.67%
3 months-17.47%
6 months-54.24%
Current year-41.69%
1 week 3.5
Extreme 3.505
4.4
1 month 3.5
Extreme 3.5
4.85
Current year 3.3
Extreme 3.305
11
1 year 1.49
Extreme 1.4895
19.4
3 years 0.82
Extreme 0.822
19.4
5 years 0.82
Extreme 0.822
19.4
10 years 0.82
Extreme 0.822
193.74
Manager TitleAgeSince
Chief Executive Officer 70 2021-07-29
Director of Finance/CFO - 2024-12-02
Chief Tech/Sci/R&D Officer - 2025-08-31
Director TitleAgeSince
Director/Board Member 60 2021-07-28
Chairman 70 2015-09-29
Director/Board Member 62 2021-07-15
Date Insider Type Main position Quantity % Market Cap.
4/19/24 Free

Director

3,000,000 0.7204%
4/19/24 Free

Director

2,000,000 0.4803%
12/22/22 Free

Chief Executive Officer

1,800,000 0.5399%
Change 5-day change 1-year change 3-year change Capi.($)
-2.30%-2.95%+123.56%+52.21% 31.29M
-0.11%-2.38%+2.06%+19.57% 48.84B
+1.89%+4.36%+494.71%+637.45% 45.44B
+1.83%+2.83%+14.87%+91.99% 41.22B
-0.50%-0.81%+25.61%+12.05% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+0.59%-2.65% - - 16.25B
-1.14%-2.01%+28.93%+132.78% 16.67B
-0.49%-0.54%+2.96%+27.12% 14.08B
-2.60%+0.79%+78.19%+39.69% 13.68B
Average -0.56%-0.77%+87.58%+118.77% 26.85B
Weighted average by Cap. -0.02%-0.84%+104.54%+155.23%

Financials

2024 2025
Net sales - -
Net income -2.48M -3.36M -2.9M -2.73M -4.67M -322M -4.74M -32.04M -12.53M -161M -12.6M -12.34M -536M -1.81M -2.45M -2.11M -1.99M -3.4M -234M -3.45M -23.32M -9.12M -117M -9.17M -8.98M -390M
Net Debt -237K -321K -277K -260K -446K -30.67M -453K -3.06M -1.2M -15.37M -1.2M -1.18M -51.17M -1.35M -1.83M -1.58M -1.49M -2.54M -175M -2.58M -17.44M -6.82M -87.72M -6.86M -6.72M -292M
Logo ImmuPharma plc
ImmuPharma PLC is a specialist drug discovery and development company. The Company is engaged in the development of drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases with high medical need. Its lead program, P140, is a non-immunosuppressing, convenient and safe peptide treatment for autoimmune disease, which is in late-stage development for the treatment of systemic lupus erythematosus (SLE) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Its pipeline products in the anti-infectives inflammation therapeutic areas include BioAMB and BioCin. BioAMB is an advanced anti-infective candidate. It is an improved form of amphotericin-B (AMB), a systemic antifungal drug. BioCin is an improved form of vancomycin, a systemic antibacterial which is highly effective against Methicillin-resistant Staphylococcus Aureus (MRSA) and orally against Clostridium Difficile infections.
Employees
7
Date Price Change Volume
26-08-18 GBX 3.615 -2.30% 1,592,075
26-08-17 GBX 3.700 -15.72% 1,204,790
26-08-14 GBX 4.390 +7.07% 2,316,749
26-08-13 GBX 4.100 +13.89% 1,246,997
26-08-12 GBX 3.600 -2.70% 2,177,315